Pathios Therapeutics
Health Care · Biotechnology
$26.4Mraised in 21 rounds
1000+people
18stories in the press
2017founded
Financials
Total raised
$26.4M
Latest round
Venture - Series Unknown
Funding rounds
21
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | — | Details |
| Venture - Series Unknown | 2025 | — | Details |
| Venture - Series Unknown | 2025 | — | Details |
| Venture - Series Unknown | 2025 | — | Details |
| Grant | 2024 | $604k | Details |
| Venture - Series Unknown | 2024 | — | Details |
| Series B | 2024 | $25M | Details |
| Venture - Series Unknown | 2024 | — | Details |
| Venture - Series Unknown | 2023 | — | Details |
| Venture - Series Unknown | 2023 | — | Details |
| Grant | 2022 | $401k | Details |
| Venture - Series Unknown | 2021 | — | Details |
| Grant | 2021 | $112k | Details |
| Venture - Series Unknown | 2021 | — | Details |
| Venture - Series Unknown | 2020 | — | Details |
| Grant | 2020 | $287k | Details |
| Venture - Series Unknown | 2020 | — | Details |
| Venture - Series Unknown | 2019 | — | Details |
| Venture - Series Unknown | 2019 | — | Details |
| Venture - Series Unknown | 2019 | — | Details |
| Venture - Series Unknown | 2018 | — | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Brandon CapitalVia a fund
Canaan PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Pathios Therapeutics Announces Promising Clinical Progress for First-in-Class GPR65 Antagonist PTT-4256 at ASCO 2026
OXFORD, UK - 5 June, 2026 High-quality biomarker data confirms successful GPR65 target engagement and intratumoral immune activation Dose-proportional pharmacokinetic profile validates the viability of patient-friendly, once-daily oral dosing Early signal
Read more
Report
Pathios Published in Cancers 2026, A Novel Approach in Renal Cell Carcinoma
OXFORD, UK - 16 December, 2025 - Pathios, in collaboration with Weatherden, was recently featured in Cancers 2026 with a review examining the role of GPR65 in renal cell carcinoma (RCC). The review highlights compelling characteristics of RCC that support
Read more
Report
Pathios Therapeutics Unveils First Public Clinical Data for First-in-Class GPR65 Antagonist PTT-4256 at SITC 2025
OXFORD, UK - 11 November, 2025 First-in-human RAISIC-1 trial demonstrates favourable safety and tolerability profile across four dose levels with zero dose-limiting toxicities (DLTs) Early clinical benefit achieved, with four patients experiencing stable
Read more
Report
Pathios Therapeutics Appoints Jon Wigginton, M.D., as Non-Executive Director
OXFORD, UK - September 24, 2025 - Pathios Therapeutics Limited ("Pathios"), a biotech company advancing the first clinical GPR65 antagonist program in cancer, today announced that Jon Wigginton, M.D., has been appointed as a non-executive director to the
Read more
Report
Pathios Therapeutics Appoints Jon Wigginton, M.D., as Non-Executive Director
/PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company advancing the first clinical GPR65 antagonist program in cancer, today announced...
Read more
Report
Pathios Therapeutics Appoints Sumeet Ambarkhane, M.D., as Chief Medical Officer
OXFORD, UK - March 24, 2025 - Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced the appointment of Sumeet Ambarkhane, M.D., as Chief Medical Officer (CMO). A phys
Read more
Report
Pathios Therapeutics Appoints Sumeet Ambarkhane, M.D., as Chief Medical Officer
Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced the appointment of Sumeet Ambarkhane, M.D., as Chief Medical Officer (CMO). A physician by training, Dr. Ambarkh
Read more
Report
Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers
MELBOURNE, AUSTRALIA and OXFORD, UK - November 20, 2024 Pathios Therapeutics ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced dosing of the first patient in the initial module of a Phase 1/2
Read more
Report
Pathios Therapeutics Appoints Paul G. Higham as Chief Executive Officer as Company Prepares to Enter the Clinic
OXFORD, UK - July 9, 2024 Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced the appointment of experienced biotechnology industry executive, Paul G. Higham, as Ch
Read more
Report
Pathios Therapeutics: $25 Million Closed For Developing Cancer Therapies
Pathios Therapeutics Limited, a biotech company focused on developing first-in-class therapies for cancer, announced that the company has raised $25 million in the first close of a Series B funding round. This funding round consists of a new strategic inv
Read more
Report
Show more news